(Q37612693)

21 August 2017

1 reference

title

Beyond glycemic control: treating the entire type 2 diabetes disorder (English)

1 reference

21 August 2017

0 references

Stephen Brunton

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

21 August 2017

published in

Postgraduate Medicine

1 reference

21 August 2017

volume

121

1 reference

21 August 2017

issue

5

1 reference

21 August 2017

page(s)

68-81

1 reference

Economic costs of diabetes in the U.S. In 2007.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Obesity and disease management: effects of weight loss on comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

National trends in treatment of type 2 diabetes mellitus, 1994-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Management of Type 2 diabetes: the role of incretin mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.09.2054

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.09.2054

1 reference

21 August 2017

1 reference